Skip to main content

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

--News Direct--

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/incannex-readying-for-phase-2-clinical-trial-of-anti-inflammatory-drug-ihl-675a-480207835

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.30
+1.05 (0.46%)
AAPL  269.70
+0.70 (0.26%)
AMD  264.33
+6.32 (2.45%)
BAC  52.58
-0.29 (-0.55%)
GOOG  275.17
+6.74 (2.51%)
META  751.67
+0.23 (0.03%)
MSFT  541.55
-0.52 (-0.10%)
NVDA  207.04
+6.01 (2.99%)
ORCL  275.30
-5.53 (-1.97%)
TSLA  461.51
+0.96 (0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.